ARCTURUS THERAPEUTICS HOLDIN (ARCT)
US03969T1097 - Common Stock
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024
Arcturus Therapeutics Holdings Enters Oversold Territory (ARCT)
First Week of May 17th Options Trading For Arcturus Therapeutics Holdings (ARCT)
ARCT Stock Earnings: Arcturus Therapeutics Beats EPS, Misses Revenue for Q4 2023
ARCT stock results show that Arcturus Therapeutics beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.
ARCT Stock Earnings: Arcturus Therapeutics Beats EPS, Misses Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Arcturus Therapeutics (NASDAQ:ARCT) just reported results for the fourth quarte...
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
Although the health innovation space can be a risky environment, undervalued biotech stocks can take some of the edge off.
Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference
Arcturus gets EU orphan drug status for cystic fibrosis drug (NASDAQ:ARCT)
Arcturus Therapeutics (ARCT) has received orphan drug designation from the European Commission for its drug candidate ARCT-032 in the treatment of cystic fibrosis. Read more here.
Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic Fibrosis
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for February 2024
Biotech stocks are often at the forefront of innovation. These picks are worth considering for your portfolio for their growth potential.
3 Tech Stocks That Could Be Multibaggers in the Making: February Edition
We have researched tech stocks for you and have found these three are likely multibaggers in the making. Considering picking them up today.
Arcturus Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 7, 2024
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
Study conducted by Meiji Seika Pharma in Japan Short communication follows previously published data in The Lancet Infectious Diseases demonstrating...
PassPort Technologies Commences Collaborative Research with Arcturus Therapeutics to Evaluate Transdermal mRNA delivery systems
/PRNewswire/ -- PassPort Technologies, Inc. (PPTI), led by President and CEO Tomoyuki Fujisawa in California, USA is pleased to announce the initiation of a...
Commit To Buy Arcturus Therapeutics Holdings At $22.50, Earn 16.2% Annualized Using Options
CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
/PRNewswire/ -- Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics (Nasdaq: ARCT) today announced the publication in Lancet...
7 Undervalued Biotech Stocks That are Flying Under the Clinical Radar
While the broader healthcare sector offers myriad opportunities, these undervalued biotech picks could offer robust upside.
3 Biotech Stocks With Promising Pipelines and Big Growth Potential in 2024
These biotech stocks with promising pipelines are showing some major promise and growth potential for the new year.
Arcturus Therapeutics' Lung Disease Candidate Triggers Bullish Rating, Analyst Sees Over 200% Upside
Canaccord Genuity has initiated coverage on Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT), a player in the genetic medicine space.
Canaccord starts Arcturus at buy; cites CF drug, COVID-19 vaccine (NASDAQ:ARCT)
Canaccord Genuity has initiated coverage of Arcturus Therapeutics (ARCT) with a buy rating, citing its cystic fibrosis drug candidate and COVID-19 vaccine. Read more here.
Arcturus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Arcturus, CSL self-amplifying mRNA vaccine approved in Japan (NASDAQ:ARCT)
Arcturus Therapeutics (ARCT) and CSL (CSLLY) have secured regulatory clearance for the world's first self-amplifying mRNA COVID-19 vaccine in Japan. Read more here.
Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adults
Exclusive Partner in Japan, Meiji Seika Pharma advances regulatory approval This historic approval of the world's first Self-Amplifying messenger RNA (sa-mRNA)...
